**K Pandiyan of Saimirra Innopharm Honored with Tamil Nadu IPA Best Pharmacist Award 2024** In a moment of pride for...

# Highlighting the Best: Top 5 Social Media Posts of 2024 Social media has become the heartbeat of global communication,...

# Highlighting the 5 Most Engaging Social Media Posts of 2024 Social media continues to evolve as a powerful platform...

**Sensorion Successfully Enrolls First Cohort in Phase I/II Gene Therapy Clinical Trial** Sensorion, a pioneering clinical-stage biotechnology company specializing in...

**PDMA Requests Prime Minister’s Support to Extend Compliance Deadline for MSMEs on Revised GMP Standards** In a significant development for...

# Discover the Best: Top 5 Podcast Episodes of 2024 Podcasts have become a staple of modern entertainment and education,...

**Discover the Best of 2024: Our Top 5 Must-Listen Podcast Episodes** Podcasts have become an integral part of our daily...

# Discover the Best of 2024: Our Top 5 Podcast Episodes Podcasts have become an integral part of our daily...

**New Discovery Reveals Healthy Tissue May Mimic Invasive Cancer in Appearance** In a groundbreaking revelation, researchers have uncovered a phenomenon...

**Study Reveals Healthy Tissue Can Mimic Characteristics of Invasive Cancer** In a groundbreaking discovery, researchers have uncovered that healthy tissue...

**New Discovery Reveals Healthy Tissue May Mimic Invasive Cancer Characteristics** In a groundbreaking revelation, researchers have uncovered that certain healthy...

**Study Reveals Healthy Tissue May Mimic Characteristics of Invasive Cancer** In a groundbreaking discovery, researchers have uncovered evidence that certain...

**India Urged to Address the Neglected Public Health Challenge of Rare Diseases: Insights from Prof. Ramaiah Muthyala** Rare diseases, often...

**India Urged to Address the Overlooked Public Health Crisis of Rare Diseases: Insights from Prof. Ramaiah Muthyala** Rare diseases, often...

**SOCRA 2024 Highlights and Key Insights: Preparing for 2025** The Society of Clinical Research Associates (SOCRA) Annual Conference is one...

**SOCRA 2024 Highlights and Key Insights: Looking Ahead to 2025** The Society of Clinical Research Associates (SOCRA) Annual Conference is...

**How Animated Explainers Revolutionize Cohort Recruitment Strategies** In today’s fast-paced digital landscape, organizations are constantly seeking innovative ways to attract,...

**Understanding Why Cancer Risk Declines with Age: New Insights Revealed** Cancer is often associated with aging, as the risk of...

**Study Reveals Up to 13% of Dementia Diagnoses May Be Treatable and Misdiagnosed Conditions** Dementia is a term that strikes...

**New Discovery: Sugar Gel Promotes Significant Hair Regrowth** In a groundbreaking development in the field of dermatology and hair restoration,...

**Innovative Sugar Gel Proven to Stimulate Significant Hair Regrowth** Hair loss is a common concern that affects millions of people...

**WAC 2024 Drives Over USD 150 Million in Business Opportunities** The World Annual Conference (WAC) 2024 has emerged as a...

**Top 5 Most Watched Conference Video Interviews of 2024** In the fast-paced world of technology, business, and innovation, conferences have...

# Top 5 Most Popular Conference Video Interviews of 2024 In the fast-paced world of business, technology, and innovation, conferences...

# Enhancing Global Compliance: The Role of an FSP PV Partner Beyond Regulatory Intelligence In the ever-evolving landscape of global...

**Ensuring Global Compliance: The Role of an FSP PV Partner Beyond Regulatory Intelligence** In the ever-evolving landscape of global pharmacovigilance...

**Addressing Clinical Trial Diversity Objectives Using Incomplete Data** Clinical trials are the cornerstone of medical research, providing the evidence needed...

**Hidden Fungi in Your Nose: What Your Sniffles Might Be Telling You** When you think of fungi, your mind might...

NICE Recommends Pfizer’s Migraine Medicine for Treatment

NICE (National Institute for Health and Care Excellence) has recently recommended Pfizer’s migraine medicine for the treatment of migraines. This recommendation comes as a significant development in the field of migraine treatment, offering new hope for millions of people suffering from this debilitating condition.

Migraines are a neurological condition characterized by severe headaches, often accompanied by other symptoms such as nausea, vomiting, and sensitivity to light and sound. They can significantly impact a person’s quality of life, causing them to miss work or social activities and leading to a decreased overall well-being.

Pfizer’s migraine medicine, whose generic name is erenumab, belongs to a class of drugs called calcitonin gene-related peptide (CGRP) inhibitors. CGRP is a protein that plays a crucial role in the development of migraines. By inhibiting CGRP, erenumab helps prevent migraines from occurring or reduces their frequency and severity.

The NICE recommendation means that erenumab will now be available through the National Health Service (NHS) in the UK for eligible patients. This is excellent news for migraine sufferers who have been eagerly awaiting new treatment options.

The recommendation was based on clinical trials that demonstrated the effectiveness of erenumab in reducing the number of migraine days experienced by patients. In one study, patients who received erenumab experienced an average of 3.7 fewer migraine days per month compared to those who received a placebo.

Furthermore, erenumab has shown to be well-tolerated by patients, with minimal side effects reported. This is particularly important as many existing migraine medications can cause significant side effects, making them unsuitable for some individuals.

The NICE recommendation also takes into account the cost-effectiveness of erenumab. While the drug is relatively expensive, NICE has determined that its benefits outweigh the costs, especially considering the significant impact migraines can have on individuals and society as a whole.

It is important to note that erenumab is not suitable for everyone. NICE recommends its use for patients who have at least four migraine days per month and have tried at least three other preventive treatments without success. Additionally, it is crucial for patients to consult with their healthcare providers to determine if erenumab is the right treatment option for them.

The availability of erenumab through the NHS will undoubtedly bring relief to many migraine sufferers who have been struggling to find an effective treatment. It represents a significant step forward in the management of migraines and offers hope for a better quality of life for those affected by this condition.

In conclusion, NICE’s recommendation of Pfizer’s migraine medicine, erenumab, for the treatment of migraines is a positive development in the field of migraine management. This medication has shown promising results in reducing the frequency and severity of migraines, with minimal side effects. Its availability through the NHS will provide much-needed relief for eligible patients and improve their overall well-being. However, it is essential for individuals to consult with their healthcare providers to determine if erenumab is the right treatment option for them.